

# Index

---

- abl oncogene, 103
- acetylaminofluorene (AAF) labelled probes, 21, 28
- adenovirus, cryptogenic disease and, 79–80
- adenovirus-2, life cycle in cells, 87
- Aleutian mink disease parvovirus, host cell interactions with, 81
- alkaline phosphate
  - in immunohistology, 82
  - probe cross-linking to, 22, 27
- allylamine-UTP labelled probes, 39
- Alzheimer's disease, 64
- $\gamma$ -aminobutyric acid (GABA) receptor
  - alpha subunit, 62
- 3-aminopropyltriethoxysilane, 71
- $\beta$ -amyloid gene, Alzheimer's disease and, 64
- anaemia, chronic haemolytic, aplastic crises in, 77
- anogenital warts in children, 77
- antibodies
  - to avidin, 28
  - to biotin, 27–8
  - to nucleic acid, 97
- antigenic site damage in hybridization
  - prior to immunocytochemistry, 41
- aplastic crises in chronic haemolytic anaemia, 77
- atheromatous disease, viruses implicated in, 79–80
- atrial natriuretic peptide, 42–3
- autoradiography, 26, 58–60
  - controls, 30
  - quantitative, 58–60
- avidin, biotinylated probe detection and, 20–1, 27, 28
- background (to signal)
  - with biotinylated probes, 20, 72
  - with RNA probes, post-hybridization reduction, 14–15
  - tissue pretreatment in reduction of, 8
  - in viral disease studies, 72–3
- biotinylated probes, 19–21, 26–8, 39
  - background problems, 20, 72
  - detection, 26–8, 39, 40
- bladder tumours, 104
- brain paste radioactive standards, quantitative autoradiography employing, 58–60
- breast cancer, 104
- bromodeoxyuridine labelled probes, 22, 28
- calcitonin gene-related peptide, 44, 45
- cancer, *see* tumours *and specific types and tissues*
- carcinoma
  - cervical (=cervical cancer), 85, 86
  - hepatocellular, 85
  - lung, small cell, 48
  - nasopharyngeal, 85
- cardiac tissue, atrial natriuretic peptide, 42
- cell(s)
  - cultures, *see* cultures
  - host, viruses in, 80–8
  - life cycles, 87–8
- central nervous system, *see* nervous system
- cervical cancer, 85, 86
- cholecystokinin, 56, 57, 58, 59, 61
- choline acetyltransferase in motor neuron disease, 63
- chromosomes
  - in tumours
    - aberrations, 103–4
    - interphase, 103–5
    - metaphase, 102
    - viral DNA integration, 86–7
  - controls, hybridization, 7, 29–31
  - in neurological studies, 56–7
  - in viral disease studies, 72–3
- corticotrophin-releasing peptide, 53
- cross-linking fixatives, 5

*In Situ Hybridization: Medical Applications*

- cryostat sections, 3
- cryptogenic disease, viral involvement in, 79–80
- cultures, cell/tissue
  - fixation, 4
  - preparation, 4
- cytochemistry, *see* immunocytochemistry
- cytogenetics, molecular, 97–109
- cytomegalovirus
  - cryptogenic disease and, 79, 80
  - detection in disease, 75–6
  - host cell interactions with, 81, 82, 83, 88
  - life cycle, intracellular, 88
- cytometry, DNA, with tumours, 104
- denaturation of DNA/nucleic acid, 8–9, 22–3
- deoxyribonucleic acid, *see* DNA
- deoxyUTP (dUTP), biotinylated, 20
- detergents, tissue pretreatment with, 7
- development of autoradiographic emulsions, 26
- dextran sulphate, 25
- diabetes mellitus, cytomegalovirus and, 80
- diethyl-pyrocabonate, solutions treated with, 6
- digoxigenin labelled probes, 21–2
- DNA
  - denaturation, 8–9, 22–3
  - probes, *see* DNA probes
  - as target
    - DNase-treated controls with, 7, 73
    - RNase pretreatment with, 7
    - viral, chromosomal integration, 86–7
- DNA flow cytometry with tumours, 104
- DNA polymerase
  - E. coli*
    - Klenow fragment, *see* Klenow fragment
    - in nick translation, 9
  - T. aquaticus*, probe production using, 68–9
- DNA probes
  - double stranded, 9–11
    - concentrations, 23–4
    - in viral disease studies, 68
  - hapten-modified, 98, 100, 101
  - single stranded, 11–12
- DNA:RNA hybrids, antibodies to, 97
- DNase, DNA target controls treated with, 7, 73
- DNase I, nick translation employing, 9
- double stranded probes, *see* probes
- duck hepatitis B virus, host cell interactions with, 81
- emulsions, autoradiographic, 26, 55–6
- encephalitis, *see also* panencephalitis
  - HIV-I, 82
  - HSV detection, 75
- endocrine cells, functional changes in, 46–7
- endocrine tumours, peptides secreted by, 48
- endothelin, 44–5
- enkephalin, 62
- enzymes
  - hybridization pretreatment of tissue with, 7
  - probe crosslinking to, 22, 27
  - detection methods employing, 27
- Epstein–Barr virus
  - chromosomal integration, 86
  - cryptogenic disease and, 79
  - host cell interactions with, 85, 86, 87
  - life cycle, intracellular, 87
  - tumourigenesis and, 85
- erythema infectiosum, 77
- expression, gene, quantification, *see* quantification
- fetus
  - hydrops, 77–8
  - parvovirus infection, 82–3
- film, probe signal previewed with, 17, 26
- resolution of, 55–6
- 5'-terminal labelling, 12
- fixation, 2–6
  - time, 3, 5
- fixative, choice, 4–6
- flow cytometric nuclear DNA measurements with tumours, 104
- fluorescein, probe detection employing, 27
- fluorescence (in general), nucleic acid
  - probe detection via, 27, 97–101
  - multiple, 100–1
- formamide, 25–6
- freezing of tissue, post-fixation cryoprotection before, 3
- frozen tissue, fixation of sections cut from, 3

## Index

- functional studies
  - of endocrine cells, 46–7
  - of nervous tissue, 61–2
- G protein, 62
- G protein-linked receptor families, 62
- GABA receptor alpha subunit, 62
- gastrin-releasing peptide, 47
- GC-rich segments, non-specific hybridization with, 57
- gene
  - expression, quantification, *see* quantification
  - mapping, 101–2
- genital warts in children, 77
- gold, colloidal, labelling with, 69
- haemolytic anaemia, chronic, aplastic
  - crises in, 77
- hairy cell leukaemia, 85
- hapten-modified nucleic acid probes, 98, 100, 101
- heart, atrial natriuretic peptide, 42
- heparin in immunocytochemistry before hybridization, 41
- hepatitis virus
  - murine, host cell interactions with, 81
  - squirrel, host cell interactions with, 80–1
  - type B
    - biotinylated, 69
    - chromosomal integration, 86
    - duck, 81
    - hepatocellular carcinoma and, 85
    - host cell interactions with, 81, 83, 84, 85, 86
  - type D (delta), host cell interactions with, 83
- hepatocellular carcinoma, 85
- herpes simplex virus
  - cryptogenic disease and, 79
  - detection in disease, 75, 79
  - host cell interactions with, 83, 84–5, 86, 88
  - life cycle, intracellular, 88
  - probes to, 70
  - tumourigenesis, 86
- herpes virus
  - in Marek's disease, 79
  - type 6, human, host cell interactions with, 81
- histology, *see* immunocytochemistry/  
immunohistology
- Hodgkin's lymphoma, 85
- homologies
  - related virus, low stringency hybridization detecting, 74
  - unexpected, misleading results with, 56–7
- human herpes virus 6, host cell interactions with, 81
- human immunodeficiency virus-I
  - chromosomal integration, 86
  - detection in disease, 79
  - host cell interactions with, 81, 82, 86, 87
  - life cycle, intracellular, 87
- human papilloma virus
  - chromosomal integration, 86
  - detection in disease, 75–6
  - host cell interactions with, 82, 83, 85, 86
  - probes to, 70
  - tumourigenesis and, 85, 86
  - types 1 to 4, 77
  - types 6 and 11, 76, 77
  - types 16 and 18, 77
  - types 31/33/35, 77
- human parvovirus
  - B19
    - detection in disease, 77–8
    - host cell interactions with, 82
  - fetal, 82–3
- hybridization, 22–5, 29–31, *see also* prehybridization
  - controls, *see* controls
  - immunocytochemistry combined with, *see* immunocytochemistry
  - probe binding in, *see* probe
  - rate/rapidity, 23–6, 75–6
    - factors affecting, 23–6
  - reproducibility, 30
  - sensitivity, 74–5
  - stringency/specificity/selectivity, *see* specificity; stringency
  - tissue pretreatment, 6–9
- hydrogen-3 (tritium) labels, 17, 18, 69
- hydrolysis of RNA probes, 14
- hydrops, fetal, 77–8
- 5-hydroxytryptamine<sub>1C</sub> receptor, 62
- immunocytochemistry/immunohistology, 37–51, 82–3

- biotin in, 20
- in situ* hybridization combined with, 37–51, 82–3
  - methodology, 39–40
  - regulatory peptides studied via, 37–51
  - virus–host cell interactions studied via, 82–3
  - nucleic acid detection via, 97–8
- interphase cytogenetics in tumours, 103–5
- iodine-125 labels, 17, 18–19
- ion channel receptor families, 62
- isotopes, radio-, 16–19, 54–5
- JC papovirus, host cell interactions with, 81, 82
- Klenow fragment
  - in M13 derived probe manufacture, 11
  - in oligonucleotide labelling, 12
  - in random primer labelling, 10–11
- Kunitz protease inhibitor, Alzheimer's disease and, 64
- label, choice, 16–22, 39, 69–70, *see also specific (types of) labels*
- latent virus infection, diagnosis, 78–9
- leucoencephalopathy, progressive multifocal (PMLE), 81, 82
- leukaemia
  - chronic myeloid, 103
  - hairly cell, 85
- liver transplantation, cytomegalovirus infection in, 75–6
- localization studies, 42–5, 61
  - in nervous tissue, 44, 44–5, 61
  - of regulatory peptides, 42–5
- lung
  - atrial natriuretic peptide, 42–3
  - small cell carcinoma, 48
- lymphomas, Hodgkin's/non-Hodgkin's/T-cell, 85
- M13 derived probes, 11
- mapping, gene, 101–2
- Marek's disease virus, 79–80
- measles virus
  - cryptogenic disease and, 79
  - detection in disease, 79
  - host cell interactions with, 83
  - probes to, 70
- mercurated probes, 21, 28–9
- metaphase chromosomes of tumour, 102
- microscopy
  - dark field, 18, 26, 55–6
  - light field, 18, 26
- minute virus of mouse, life cycle in cells, 79
- motor neurone disease, 63
- mouse/murine viruses, *see* hepatitis virus; minute virus of mouse; Theiler's disease murine picornavirus; Theiler's murine encephalitis virus
- myelodysplastic syndrome, 103
- myeloid leukaemia, chronic, 103
- nasopharyngeal carcinoma, 85
- nervous system, 52–65
  - disorders, 63
  - peptides in, 52–65
    - localization, 44, 44–5, 61
- neuropeptide(s), *see specific peptides*
- neuropeptide Y, 44
- nick translation, 9–10
- non-radioactively labelled probes, 19–21, 26–9, 30–1, 98–101
  - controls, 30–1
  - current status, 99
  - detection, 26–9, 30–1
  - structure/properties/characteristics, 19–21
    - in viral disease studies, 69, 70
  - nucleation stage in hybridization, 23
- nucleic acid, *see also* DNA; RNA
  - antibodies to, 97
  - hapten-modified, 98, 100, 101
- oligonucleotide probes, synthetic, 11–12
  - in viral disease studies, 68
- ovarian cancer cytogenetics, 102
- panencephalitis, subacute sclerosing, 79
- papilloma virus, *see* human papilloma virus
- papovirus, JC, host cell interactions with, 81, 82
- paraffin embedded sections, 3–4
- paraformaldehyde fixative, 5
- parvovirus
  - Aleutian mink disease, host cell interactions with, 81
  - human, *see* human parvovirus
  - life cycle in cell, 87
- peptides, regulatory, 37–51
  - in endocrine cells, functional changes in levels, 46–7
- in situ* hybridization combined with

## Index

- immunocytochemistry in studies of, 37–51
  - localization, 42–5
  - quantification, 47–8
  - in tumours, 48
- permeability, tissue pretreatment increasing, 7, 54
- peroxidase, cross-linking to probe, 22, 27
- Philadelphia chromosome, 103
- phosphorus-32 labels, 17, 17–18, 18, 69
- pHY2.1, 71
- pituitary, prolactin, 46
- plasmid RNA probe, *see* RNA probes
- polyethylene-imine, enzyme-probe cross-linking employing, 22
- polymerase chain reaction, probe production using, 68–9
- polynucleotide kinase (T4) labelling of 5'-ends, 12
- potato spindle tuber virus, life cycle in cell, 87
- prehybridization, 8–9, 54
- $\beta$ -prepro-tachykinin, 48
- prepro-tachykinin-A, 62
- priming, random, 10–11
- probes, 9–16, 26–9, 29–30
  - background problems, *see* background
  - binding/hybridization, 29–30
    - non-specific, 29–30, 57
    - specific, 29
  - choice/types, 38, 54–5, *see also specific types*
    - in immunocytochemistry and *in situ* hybridization combined, 38
    - in neurological studies, 54–5
    - in viral disease studies, 68–9
  - concentration, 23–4
  - detection (of signal), 26–9, 55
    - controls in the, 30–1
  - double stranded, 9–11, 23–4
  - disadvantages, 14, 15–16
  - hybridization, *see* hybridization
  - labelled/labelling
    - non-radioactive, *see* non-radioactively labelled probes
    - radioactive, *see* radioactively labelled probes
  - length, 34–5
  - single stranded, 11–12, 23
    - advantages, 14, 15–16, 38
    - synthetic, 11–12
  - processing of autoradiographic emulsions, 26
  - prolactin, 46
  - pro-opiomelanocortin, 47
  - proteolytic enzymes, hybridization pretreatment of tissue with, 7, 71–2
- pSP64, 12
- pulmonary tissue, *see* lung
- quantification/quantitation (of mRNA/gene expression), 47–8, 58–60
  - autoradiographic, 58–60
  - in neurological studies, 54, 56, 58–60
  - in regulatory peptide studies, 47–8
- radioactive standards, quantitative autoradiography employing tissues containing, 58–60
- radioactively labelled probes, 16–19, 30, 69
  - controls with, 30
  - detection, 26, 30
  - isotopes, 16–19, 54–5
  - structure/properties/characteristics, 16–19
    - in viral disease studies, 69, 70
- radioisotopes, 16–19, 54–5
- random primer labelling, 10–11
- regulatory peptides, *see* peptides
- resolution in neurological studies, 55–6
- restriction fragment length polymorphisms in tumours, 105
- rhodamine, probe detection employing, 27
- RNA, target, RNase-treated controls with, 7, 56, 58, 61, 73
- mRNA
  - expression, quantification, *see* quantification
  - in functional activity indices, assays of, 53–4
- RNA:DNA hybrids, antibodies to, 97
- RNA probe(s), 12–16
  - in combined immunocytochemical and *in situ* hybridization studies, 38
  - concentrations, 23
  - plasmids vectors in the production of, 38
  - in viral disease studies, 68
- RNase
  - background reduction using, post-hybridization, 14

*In Situ Hybridization: Medical Applications*

- DNA target tissue pretreated with, 7, 73
- hybridization free of, 6
- RNA target controls treated with, 7, 56, 58, 61, 73
- RNase inhibitor in immunocytochemistry before hybridization, 41
- salt concentration in hybridization, 24
- sections, fixation, 3–4
- sensitivity of hybridization, 74–5
- sexual abuse, anogenital warts as evidence of, 77
- single stranded probes, *see* probes
- Sjögren's syndrome, Epstein-Barr virus and, 79
- slow virus infection, diagnosis, 78–9
- small cell lung carcinoma, 48
- specificity, probe, 29, *see also* stringency
- squirrel hepatitis virus, host cell interactions with, 80–1
- standards, radioactive, quantitative autoradiography employing tissues containing, 58–60
- streptavidin, biotinylated probe detection and, 20, 27
- stringency of hybridization, 24, 25, 29, *see also* specificity
  - in viral disease studies, 72, 74–77
- substance K, 62
- substance P, 44, 45
- sulphonated probes, 22
- sulphur-35 labels, 17, 69
  - in viral disease studies, 69
- synthetic probes, 11–12
- T cell lymphoma, 85
- T4 polynucleotide kinase labelling of 5'-ends, 12
- tachykinin, *see* prepro-tachykinin
- temperatures, hybridization, 24
- terminal deoxynucleotidyl transferase labelling of 3'-ends, 12
- Theiler's disease murine picornavirus, 84
- Theiler's murine encephalitis virus, 83
- Thermus aquaticus* DNA polymerase, probe production using, 68–9
- 3'-terminal labelling, 12
- $\beta$ -thyroid-stimulating hormone, 47, 48
- tissue
  - cultures, *see* cultures
  - handling, 2–4
  - hybridization, *see* hybridization
  - preparation, 2–9, 54
    - in viral disease studies, 71–2
    - proteolytic digestion, 7, 71–2
  - transplantation, liver, cytomegalovirus infection in, 75–6
- tritium labels, 17, 18, 69
- tumours, 48, 85–6, 102–5, *see also specific types and tissues*
  - cytogenetics, 102–5
  - development, viruses associated with, 85–6
  - peptides secreted by, 48
- ultrastructural studies of viral life cycles in cells, 88
- UTP
  - allylamine-, 39
  - biotin-, 19, 20, 39
- varicella zoster virus
  - detection in disease, 79
  - host cell interactions with, 85
- vasopressin, 53
- viruses, 66–96, *see also specific viruses*
  - disease caused by, *in situ* hybridization with, 66–96
    - diagnostic applications, 73–80
    - methodology, 68–73
  - host cell interactions with, 80–7
  - life cycles in cells, 87–8
  - related, low stringency hybridization detecting, 74
- visna virus
  - detection in disease, 74
  - host cell interactions with, 80, 82, 83, 84
  - probes to, 70
- warts, genital/anogenital, in children, 77
- X-ray film, probe signal previewed with, 17, 26
  - resolution, 55
- Y chromosome, pHY2.1 and the, 71
- yellow fever virus, host cell interactions with, 81
- zippering stage in hybridization, 23